Titre : Congénères de la progestérone

Congénères de la progestérone : Questions médicales fréquentes

Termes MeSH sélectionnés :

Radiotherapy, Intensity-Modulated

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer un déséquilibre hormonal lié aux congénères ?

Un diagnostic se fait par des tests sanguins mesurant les niveaux hormonaux.
Déséquilibre hormonal Progestérone Tests sanguins
#2

Quels symptômes indiquent un besoin de tester les congénères ?

Des irrégularités menstruelles, des douleurs pelviennes ou des symptômes de ménopause.
Irrégularités menstruelles Symptômes de ménopause Douleurs pelviennes
#3

Quels examens sont recommandés pour évaluer les congénères ?

Des analyses hormonales et éventuellement une échographie pelvienne.
Analyses hormonales Échographie pelvienne Évaluation hormonale
#4

Les tests de progestérone sont-ils fiables ?

Oui, ils sont généralement fiables pour évaluer les niveaux hormonaux.
Progestérone Tests hormonaux Fiabilité des tests
#5

Quand consulter un médecin pour des congénères ?

Si vous avez des symptômes persistants ou des préoccupations hormonales.
Consultation médicale Symptômes hormonaux Préoccupations de santé

Symptômes 5

#1

Quels sont les symptômes d'un excès de congénères ?

Des saignements irréguliers, des maux de tête et des changements d'humeur.
Saignements irréguliers Maux de tête Changements d'humeur
#2

Comment reconnaître un déficit en progestérone ?

Par des cycles menstruels irréguliers, des bouffées de chaleur et de l'anxiété.
Déficit en progestérone Bouffées de chaleur Anxiété
#3

Les symptômes varient-ils selon l'âge ?

Oui, les symptômes peuvent varier, surtout autour de la ménopause.
Ménopause Variabilité des symptômes Âge
#4

Les symptômes sont-ils similaires à ceux d'autres troubles ?

Oui, ils peuvent ressembler à ceux d'autres déséquilibres hormonaux.
Déséquilibres hormonaux Troubles hormonaux Symptômes similaires
#5

Les symptômes peuvent-ils affecter la fertilité ?

Oui, un déséquilibre peut nuire à la fertilité et à la conception.
Fertilité Conception Déséquilibre hormonal

Prévention 5

#1

Comment prévenir les déséquilibres hormonaux ?

Maintenir un mode de vie sain, gérer le stress et consulter régulièrement un médecin.
Prévention Mode de vie sain Gestion du stress
#2

L'alimentation influence-t-elle les niveaux hormonaux ?

Oui, une alimentation équilibrée peut aider à réguler les niveaux hormonaux.
Alimentation Régulation hormonale Équilibre nutritionnel
#3

Le sport aide-t-il à équilibrer les hormones ?

Oui, l'exercice régulier peut contribuer à un meilleur équilibre hormonal.
Exercice Équilibre hormonal Santé physique
#4

Les contrôles médicaux réguliers sont-ils importants ?

Oui, ils permettent de détecter précocement les déséquilibres hormonaux.
Contrôles médicaux Dépistage précoce Déséquilibres hormonaux
#5

Le stress a-t-il un impact sur les hormones ?

Oui, le stress chronique peut perturber l'équilibre hormonal.
Stress Impact hormonal Équilibre hormonal

Traitements 5

#1

Quels traitements sont disponibles pour les déséquilibres ?

Des thérapies hormonales, des médicaments progestatifs et des changements de mode de vie.
Thérapies hormonales Médicaments progestatifs Changements de mode de vie
#2

Les traitements sont-ils personnalisés ?

Oui, les traitements sont souvent adaptés aux besoins individuels du patient.
Traitements personnalisés Besoins individuels Médecine personnalisée
#3

Les congénères peuvent-ils être administrés par voie orale ?

Oui, certains congénères de progestérone sont disponibles sous forme orale.
Voie orale Administration médicamenteuse Congénères de progestérone
#4

Y a-t-il des effets secondaires aux traitements ?

Oui, des effets secondaires comme des nausées ou des changements d'humeur peuvent survenir.
Effets secondaires Nausées Changements d'humeur
#5

Combien de temps dure un traitement hormonal ?

La durée dépend de la condition traitée, souvent plusieurs mois à plusieurs années.
Durée du traitement Conditions traitées Thérapie hormonale

Complications 5

#1

Quelles complications peuvent survenir avec un déséquilibre ?

Des complications comme l'infertilité, des troubles menstruels et des maladies cardiovasculaires.
Infertilité Troubles menstruels Maladies cardiovasculaires
#2

Les déséquilibres hormonaux augmentent-ils le risque de cancer ?

Oui, certains déséquilibres peuvent augmenter le risque de cancers hormonodépendants.
Cancer Déséquilibres hormonaux Risque de cancer
#3

Comment les complications sont-elles gérées ?

Elles sont gérées par des traitements hormonaux et un suivi médical régulier.
Gestion des complications Traitements hormonaux Suivi médical
#4

Les complications peuvent-elles affecter la santé mentale ?

Oui, des déséquilibres hormonaux peuvent entraîner des troubles de l'humeur.
Santé mentale Troubles de l'humeur Déséquilibres hormonaux
#5

Les complications sont-elles réversibles ?

Certaines complications peuvent être réversibles avec un traitement approprié.
Complications réversibles Traitement approprié Déséquilibres hormonaux

Facteurs de risque 5

#1

Quels sont les facteurs de risque pour les déséquilibres hormonaux ?

L'âge, le stress, l'alimentation et les antécédents médicaux jouent un rôle.
Facteurs de risque Antécédents médicaux Stress
#2

Le surpoids influence-t-il les niveaux hormonaux ?

Oui, le surpoids peut perturber l'équilibre hormonal et augmenter les risques.
Surpoids Perturbation hormonale Équilibre hormonal
#3

Les antécédents familiaux sont-ils un facteur de risque ?

Oui, des antécédents familiaux de troubles hormonaux peuvent augmenter le risque.
Antécédents familiaux Troubles hormonaux Facteurs génétiques
#4

Le tabagisme affecte-t-il les hormones ?

Oui, le tabagisme peut perturber les niveaux hormonaux et aggraver les symptômes.
Tabagisme Perturbation hormonale Symptômes hormonaux
#5

Le stress chronique est-il un facteur de risque ?

Oui, le stress chronique peut contribuer à des déséquilibres hormonaux significatifs.
Stress chronique Déséquilibres hormonaux Facteurs de risque
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Congénères de la progestérone : Questions médicales les plus fréquentes", "headline": "Congénères de la progestérone : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Congénères de la progestérone : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-22", "dateModified": "2026-03-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Congénères de la progestérone" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hormones sexuelles stéroïdiennes", "url": "https://questionsmedicales.fr/mesh/D012739", "about": { "@type": "MedicalCondition", "name": "Hormones sexuelles stéroïdiennes", "code": { "@type": "MedicalCode", "code": "D012739", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Prégnénolone", "alternateName": "Pregnenolone", "url": "https://questionsmedicales.fr/mesh/D011284", "about": { "@type": "MedicalCondition", "name": "Prégnénolone", "code": { "@type": "MedicalCode", "code": "D011284", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "17alpha-Hydroxypregnénolone", "alternateName": "17-alpha-Hydroxypregnenolone", "url": "https://questionsmedicales.fr/mesh/D006907", "about": { "@type": "MedicalCondition", "name": "17alpha-Hydroxypregnénolone", "code": { "@type": "MedicalCode", "code": "D006907", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.500.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Progestérone", "alternateName": "Progesterone", "url": "https://questionsmedicales.fr/mesh/D011374", "about": { "@type": "MedicalCondition", "name": "Progestérone", "code": { "@type": "MedicalCode", "code": "D011374", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "5alpha-Dihydroprogestérone", "alternateName": "5-alpha-Dihydroprogesterone", "url": "https://questionsmedicales.fr/mesh/D043582", "about": { "@type": "MedicalCondition", "name": "5alpha-Dihydroprogestérone", "code": { "@type": "MedicalCode", "code": "D043582", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.070" } } }, { "@type": "MedicalWebPage", "name": "20alpha-Dihydroprogestérone", "alternateName": "20-alpha-Dihydroprogesterone", "url": "https://questionsmedicales.fr/mesh/D004092", "about": { "@type": "MedicalCondition", "name": "20alpha-Dihydroprogestérone", "code": { "@type": "MedicalCode", "code": "D004092", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.074" } } }, { "@type": "MedicalWebPage", "name": "Hydroxyprogestérones", "alternateName": "Hydroxyprogesterones", "url": "https://questionsmedicales.fr/mesh/D006908", "about": { "@type": "MedicalCondition", "name": "Hydroxyprogestérones", "code": { "@type": "MedicalCode", "code": "D006908", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.478" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "17alpha-Hydroxyprogestérone", "alternateName": "17-alpha-Hydroxyprogesterone", "url": "https://questionsmedicales.fr/mesh/D019326", "about": { "@type": "MedicalCondition", "name": "17alpha-Hydroxyprogestérone", "code": { "@type": "MedicalCode", "code": "D019326", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.478.400" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Caproate d'hydroxyprogestérone", "alternateName": "17 alpha-Hydroxyprogesterone Caproate", "url": "https://questionsmedicales.fr/mesh/D000077713", "about": { "@type": "MedicalCondition", "name": "Caproate d'hydroxyprogestérone", "code": { "@type": "MedicalCode", "code": "D000077713", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.478.400.250" } } }, { "@type": "MedicalWebPage", "name": "Prégnanetriol", "alternateName": "Pregnanetriol", "url": "https://questionsmedicales.fr/mesh/D011279", "about": { "@type": "MedicalCondition", "name": "Prégnanetriol", "code": { "@type": "MedicalCode", "code": "D011279", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.478.400.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Caproate d'hydroxyprogestérone", "alternateName": "17 alpha-Hydroxyprogesterone Caproate", "url": "https://questionsmedicales.fr/mesh/D000077713", "about": { "@type": "MedicalCondition", "name": "Caproate d'hydroxyprogestérone", "code": { "@type": "MedicalCode", "code": "D000077713", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.478.400.250" } } }, { "@type": "MedicalWebPage", "name": "Prégnanetriol", "alternateName": "Pregnanetriol", "url": "https://questionsmedicales.fr/mesh/D011279", "about": { "@type": "MedicalCondition", "name": "Prégnanetriol", "code": { "@type": "MedicalCode", "code": "D011279", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.478.400.500" } } } ] }, { "@type": "MedicalWebPage", "name": "17alpha-Hydroxyprogestérone", "alternateName": "17-alpha-Hydroxyprogesterone", "url": "https://questionsmedicales.fr/mesh/D019326", "about": { "@type": "MedicalCondition", "name": "17alpha-Hydroxyprogestérone", "code": { "@type": "MedicalCode", "code": "D019326", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.478.400" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Caproate d'hydroxyprogestérone", "alternateName": "17 alpha-Hydroxyprogesterone Caproate", "url": "https://questionsmedicales.fr/mesh/D000077713", "about": { "@type": "MedicalCondition", "name": "Caproate d'hydroxyprogestérone", "code": { "@type": "MedicalCode", "code": "D000077713", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.478.400.250" } } }, { "@type": "MedicalWebPage", "name": "Prégnanetriol", "alternateName": "Pregnanetriol", "url": "https://questionsmedicales.fr/mesh/D011279", "about": { "@type": "MedicalCondition", "name": "Prégnanetriol", "code": { "@type": "MedicalCode", "code": "D011279", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.478.400.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Caproate d'hydroxyprogestérone", "alternateName": "17 alpha-Hydroxyprogesterone Caproate", "url": "https://questionsmedicales.fr/mesh/D000077713", "about": { "@type": "MedicalCondition", "name": "Caproate d'hydroxyprogestérone", "code": { "@type": "MedicalCode", "code": "D000077713", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.478.400.250" } } }, { "@type": "MedicalWebPage", "name": "Prégnanetriol", "alternateName": "Pregnanetriol", "url": "https://questionsmedicales.fr/mesh/D011279", "about": { "@type": "MedicalCondition", "name": "Prégnanetriol", "code": { "@type": "MedicalCode", "code": "D011279", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.478.400.500" } } }, { "@type": "MedicalWebPage", "name": "Prégnanediol", "alternateName": "Pregnanediol", "url": "https://questionsmedicales.fr/mesh/D011276", "about": { "@type": "MedicalCondition", "name": "Prégnanediol", "code": { "@type": "MedicalCode", "code": "D011276", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D06.472.334.851.687.750.739" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Congénères de la progestérone", "alternateName": "Progesterone Congeners", "code": { "@type": "MedicalCode", "code": "D045167", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sam Mesiano", "url": "https://questionsmedicales.fr/author/Sam%20Mesiano", "affiliation": { "@type": "Organization", "name": "William H Weir MD Professor of Reproductive Biology, Department of Reproductive Biology Case, Western Reserve University, USA; Department of Obstetrics and Gynecology, University Hospitals of Cleveland, 11100 Euclid Ave, Cleveland, OH 44106, USA. Electronic address: sam.mesiano@case.edu." } }, { "@type": "Person", "name": "Xiangcheng Zhu", "url": "https://questionsmedicales.fr/author/Xiangcheng%20Zhu", "affiliation": { "@type": "Organization", "name": "Xiangya International Academy of Translational Medicine at Central South University , Changsha , Hunan 410013 , People's Republic of China." } }, { "@type": "Person", "name": "Ben Shen", "url": "https://questionsmedicales.fr/author/Ben%20Shen", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Yanwen Duan", "url": "https://questionsmedicales.fr/author/Yanwen%20Duan", "affiliation": { "@type": "Organization", "name": "Xiangya International Academy of Translational Medicine at Central South University , Changsha , Hunan 410013 , People's Republic of China." } }, { "@type": "Person", "name": "Yong Huang", "url": "https://questionsmedicales.fr/author/Yong%20Huang", "affiliation": { "@type": "Organization", "name": "Xiangya International Academy of Translational Medicine at Central South University , Changsha , Hunan 410013 , People's Republic of China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Influence of radiotherapy interruption on esophageal cancer with intensity-modulated radiotherapy: a retrospective study.", "datePublished": "2024-05-27", "url": "https://questionsmedicales.fr/article/38802765", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12885-024-12383-7" } }, { "@type": "ScholarlyArticle", "name": "Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.", "datePublished": "2023-07-06", "url": "https://questionsmedicales.fr/article/37423227", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S1470-2045(23)00265-6" } }, { "@type": "ScholarlyArticle", "name": "Comparative Study of Dysphagia-optimized Intensity Modulated Radiotherapy (Do-IMRT) and Standard Intensity Modulated Radiotherapy (S-IMRT) and Its Clinical Correlation in Head and Neck Cancer Patients.", "datePublished": "2023-11-01", "url": "https://questionsmedicales.fr/article/38019227", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.31557/APJCP.2023.24.11.3697" } }, { "@type": "ScholarlyArticle", "name": "Intensity-modulated radiotherapy for cushing's disease: single-center experience in 70 patients.", "datePublished": "2023-09-26", "url": "https://questionsmedicales.fr/article/37822603", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fendo.2023.1241669" } }, { "@type": "ScholarlyArticle", "name": "Evaluation of the effect of intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc radiotherapy (VMAT) techniques on survival response in cell lines with a new radiobiological modeling.", "datePublished": "2023-09-27", "url": "https://questionsmedicales.fr/article/37754559", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cam4.6593" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Hormones gonadiques", "item": "https://questionsmedicales.fr/mesh/D042341" }, { "@type": "ListItem", "position": 3, "name": "Hormones sexuelles stéroïdiennes", "item": "https://questionsmedicales.fr/mesh/D012739" }, { "@type": "ListItem", "position": 4, "name": "Congénères de la progestérone", "item": "https://questionsmedicales.fr/mesh/D045167" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Congénères de la progestérone - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Congénères de la progestérone", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2026-05-23", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Congénères de la progestérone", "description": "Comment diagnostiquer un déséquilibre hormonal lié aux congénères ?\nQuels symptômes indiquent un besoin de tester les congénères ?\nQuels examens sont recommandés pour évaluer les congénères ?\nLes tests de progestérone sont-ils fiables ?\nQuand consulter un médecin pour des congénères ?", "url": "https://questionsmedicales.fr/mesh/D045167?mesh_terms=Radiotherapy,+Intensity-Modulated#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Congénères de la progestérone", "description": "Quels sont les symptômes d'un excès de congénères ?\nComment reconnaître un déficit en progestérone ?\nLes symptômes varient-ils selon l'âge ?\nLes symptômes sont-ils similaires à ceux d'autres troubles ?\nLes symptômes peuvent-ils affecter la fertilité ?", "url": "https://questionsmedicales.fr/mesh/D045167?mesh_terms=Radiotherapy,+Intensity-Modulated#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Congénères de la progestérone", "description": "Comment prévenir les déséquilibres hormonaux ?\nL'alimentation influence-t-elle les niveaux hormonaux ?\nLe sport aide-t-il à équilibrer les hormones ?\nLes contrôles médicaux réguliers sont-ils importants ?\nLe stress a-t-il un impact sur les hormones ?", "url": "https://questionsmedicales.fr/mesh/D045167?mesh_terms=Radiotherapy,+Intensity-Modulated#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Congénères de la progestérone", "description": "Quels traitements sont disponibles pour les déséquilibres ?\nLes traitements sont-ils personnalisés ?\nLes congénères peuvent-ils être administrés par voie orale ?\nY a-t-il des effets secondaires aux traitements ?\nCombien de temps dure un traitement hormonal ?", "url": "https://questionsmedicales.fr/mesh/D045167?mesh_terms=Radiotherapy,+Intensity-Modulated#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Congénères de la progestérone", "description": "Quelles complications peuvent survenir avec un déséquilibre ?\nLes déséquilibres hormonaux augmentent-ils le risque de cancer ?\nComment les complications sont-elles gérées ?\nLes complications peuvent-elles affecter la santé mentale ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D045167?mesh_terms=Radiotherapy,+Intensity-Modulated#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Congénères de la progestérone", "description": "Quels sont les facteurs de risque pour les déséquilibres hormonaux ?\nLe surpoids influence-t-il les niveaux hormonaux ?\nLes antécédents familiaux sont-ils un facteur de risque ?\nLe tabagisme affecte-t-il les hormones ?\nLe stress chronique est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D045167?mesh_terms=Radiotherapy,+Intensity-Modulated#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un déséquilibre hormonal lié aux congénères ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic se fait par des tests sanguins mesurant les niveaux hormonaux." } }, { "@type": "Question", "name": "Quels symptômes indiquent un besoin de tester les congénères ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des irrégularités menstruelles, des douleurs pelviennes ou des symptômes de ménopause." } }, { "@type": "Question", "name": "Quels examens sont recommandés pour évaluer les congénères ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses hormonales et éventuellement une échographie pelvienne." } }, { "@type": "Question", "name": "Les tests de progestérone sont-ils fiables ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont généralement fiables pour évaluer les niveaux hormonaux." } }, { "@type": "Question", "name": "Quand consulter un médecin pour des congénères ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Si vous avez des symptômes persistants ou des préoccupations hormonales." } }, { "@type": "Question", "name": "Quels sont les symptômes d'un excès de congénères ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des saignements irréguliers, des maux de tête et des changements d'humeur." } }, { "@type": "Question", "name": "Comment reconnaître un déficit en progestérone ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Par des cycles menstruels irréguliers, des bouffées de chaleur et de l'anxiété." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier, surtout autour de la ménopause." } }, { "@type": "Question", "name": "Les symptômes sont-ils similaires à ceux d'autres troubles ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent ressembler à ceux d'autres déséquilibres hormonaux." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils affecter la fertilité ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un déséquilibre peut nuire à la fertilité et à la conception." } }, { "@type": "Question", "name": "Comment prévenir les déséquilibres hormonaux ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un mode de vie sain, gérer le stress et consulter régulièrement un médecin." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle les niveaux hormonaux ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut aider à réguler les niveaux hormonaux." } }, { "@type": "Question", "name": "Le sport aide-t-il à équilibrer les hormones ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut contribuer à un meilleur équilibre hormonal." } }, { "@type": "Question", "name": "Les contrôles médicaux réguliers sont-ils importants ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils permettent de détecter précocement les déséquilibres hormonaux." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur les hormones ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber l'équilibre hormonal." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les déséquilibres ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies hormonales, des médicaments progestatifs et des changements de mode de vie." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés aux besoins individuels du patient." } }, { "@type": "Question", "name": "Les congénères peuvent-ils être administrés par voie orale ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains congénères de progestérone sont disponibles sous forme orale." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme des nausées ou des changements d'humeur peuvent survenir." } }, { "@type": "Question", "name": "Combien de temps dure un traitement hormonal ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La durée dépend de la condition traitée, souvent plusieurs mois à plusieurs années." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec un déséquilibre ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme l'infertilité, des troubles menstruels et des maladies cardiovasculaires." } }, { "@type": "Question", "name": "Les déséquilibres hormonaux augmentent-ils le risque de cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains déséquilibres peuvent augmenter le risque de cancers hormonodépendants." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont gérées par des traitements hormonaux et un suivi médical régulier." } }, { "@type": "Question", "name": "Les complications peuvent-elles affecter la santé mentale ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des déséquilibres hormonaux peuvent entraîner des troubles de l'humeur." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les déséquilibres hormonaux ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, le stress, l'alimentation et les antécédents médicaux jouent un rôle." } }, { "@type": "Question", "name": "Le surpoids influence-t-il les niveaux hormonaux ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le surpoids peut perturber l'équilibre hormonal et augmenter les risques." } }, { "@type": "Question", "name": "Les antécédents familiaux sont-ils un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de troubles hormonaux peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il les hormones ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut perturber les niveaux hormonaux et aggraver les symptômes." } }, { "@type": "Question", "name": "Le stress chronique est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut contribuer à des déséquilibres hormonaux significatifs." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 14/03/2026

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Sam Mesiano

3 publications dans cette catégorie

Affiliations :
  • William H Weir MD Professor of Reproductive Biology, Department of Reproductive Biology Case, Western Reserve University, USA; Department of Obstetrics and Gynecology, University Hospitals of Cleveland, 11100 Euclid Ave, Cleveland, OH 44106, USA. Electronic address: sam.mesiano@case.edu.
Publications dans "Congénères de la progestérone" :

Xiangcheng Zhu

2 publications dans cette catégorie

Affiliations :
  • Xiangya International Academy of Translational Medicine at Central South University , Changsha , Hunan 410013 , People's Republic of China.
  • Hunan Engineering Research Center of Combinatorial Biosynthesis and Natural Product Drug Discovery , Changsha , Hunan 410011 , People's Republic of China.
Publications dans "Congénères de la progestérone" :

Ben Shen

2 publications dans cette catégorie

Publications dans "Congénères de la progestérone" :

Yanwen Duan

2 publications dans cette catégorie

Affiliations :
  • Xiangya International Academy of Translational Medicine at Central South University , Changsha , Hunan 410013 , People's Republic of China.
  • Hunan Engineering Research Center of Combinatorial Biosynthesis and Natural Product Drug Discovery , Changsha , Hunan 410011 , People's Republic of China.
  • National Engineering Research Center of Combinatorial Biosynthesis for Drug Discovery , Changsha , Hunan 410011 , People's Republic of China.
Publications dans "Congénères de la progestérone" :

Yong Huang

2 publications dans cette catégorie

Affiliations :
  • Xiangya International Academy of Translational Medicine at Central South University , Changsha , Hunan 410013 , People's Republic of China.
  • National Engineering Research Center of Combinatorial Biosynthesis for Drug Discovery , Changsha , Hunan 410011 , People's Republic of China.
Publications dans "Congénères de la progestérone" :

Samir Z Zard

2 publications dans cette catégorie

Affiliations :
  • Laboratoire de Synthèse Organique, UMR 7652, Ecole Polytechnique, 91128, Palaiseau, France.
Publications dans "Congénères de la progestérone" :

Meghan Cartwright

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa. Electronic address: meghanc@sun.ac.za.
Publications dans "Congénères de la progestérone" :

Renate Louw-du Toit

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa. Electronic address: renate@sun.ac.za.
Publications dans "Congénères de la progestérone" :

Donita Africander

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa. Electronic address: drho@sun.ac.za.
Publications dans "Congénères de la progestérone" :

Keri C Hornbuckle

2 publications dans cette catégorie

Affiliations :
  • Department of Civil & Environmental Engineering, IIHR-Hydroscience and Engineering, The University of Iowa, Iowa City, IA, USA.
Publications dans "Congénères de la progestérone" :

Muhammad Aamir

1 publication dans cette catégorie

Affiliations :
  • MOE Key Laboratory of Environmental Remediation and Ecosystem Health, Institute of Environmental Health, College of Environmental and Resource Sciences, Zhejiang University, Hangzhou, 310058, China.
Publications dans "Congénères de la progestérone" :

Shanshan Yin

1 publication dans cette catégorie

Affiliations :
  • MOE Key Laboratory of Environmental Remediation and Ecosystem Health, Institute of Environmental Health, College of Environmental and Resource Sciences, Zhejiang University, Hangzhou, 310058, China.
Publications dans "Congénères de la progestérone" :

Yuting Zhou

1 publication dans cette catégorie

Affiliations :
  • MOE Key Laboratory of Environmental Remediation and Ecosystem Health, Institute of Environmental Health, College of Environmental and Resource Sciences, Zhejiang University, Hangzhou, 310058, China.
Publications dans "Congénères de la progestérone" :

Chenye Xu

1 publication dans cette catégorie

Affiliations :
  • MOE Key Laboratory of Environmental Remediation and Ecosystem Health, Institute of Environmental Health, College of Environmental and Resource Sciences, Zhejiang University, Hangzhou, 310058, China.
Publications dans "Congénères de la progestérone" :

Kai Liu

1 publication dans cette catégorie

Affiliations :
  • Department of Environmental Science and Engineering, W. M. Keck Laboratories, California Institute of Technology, 1200 East California Blvd, Pasadena, CA, 91125, USA.
Publications dans "Congénères de la progestérone" :

Weiping Liu

1 publication dans cette catégorie

Affiliations :
  • MOE Key Laboratory of Environmental Remediation and Ecosystem Health, Institute of Environmental Health, College of Environmental and Resource Sciences, Zhejiang University, Hangzhou, 310058, China. Electronic address: wliu@zju.edu.cn.
Publications dans "Congénères de la progestérone" :

Paola Oliva

1 publication dans cette catégorie

Affiliations :
  • Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Publications dans "Congénères de la progestérone" :

Asmita Pramanik

1 publication dans cette catégorie

Affiliations :
  • Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Publications dans "Congénères de la progestérone" :

Young-Hwan Jung

1 publication dans cette catégorie

Affiliations :
  • Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Publications dans "Congénères de la progestérone" :

Sarah A Lewicki

1 publication dans cette catégorie

Affiliations :
  • Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Publications dans "Congénères de la progestérone" :

Sources (10000 au total)

Influence of radiotherapy interruption on esophageal cancer with intensity-modulated radiotherapy: a retrospective study.

Radiotherapy interruption (RTI) prolongs the overall total treatment time and leads to local control loss in many cancers, but it is unclear in esophageal cancer. We aimed to evaluate the influence of... A total of 299 patients with esophageal squamous cell carcinoma from 2017 to 2019 were retrospectively analyzed to investigate the effect of RTI on OS, PFS, and LRFS. The delayed time of radiotherapy ... The 3-year OS, PFS, and LRFS rates were 53.0%, 42.0%, and 48.0%, respectively. The univariate and multivariate analyses showed that the delayed time > 3 days was an independent adverse prognostic fact... There was a significant correlation between delayed time and local control of esophageal cancer. The delayed time for more than 3 days might decrease the survival outcome, and increase the local recur...

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.

Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with chemoradiotherapy with curative intent but at the consequence of adverse effects on quality of life. We aimed to investig... DARS was a parallel-group, phase 3, multicentre, randomised, controlled trial done in 22 radiotherapy centres in Ireland and the UK. Participants were aged 18 years and older, had T1-4, N0-3, M0 oroph... From June 24, 2016, to April 27, 2018, 118 patients were registered, 112 of whom were randomly assigned (56 to each treatment group). 22 (20%) participants were female and 90 (80%) were male; median a... Our findings suggest that DO-IMRT improves patient-reported swallowing function compared with standard IMRT. DO-IMRT should be considered a new standard of care for patients receiving radiotherapy for... Cancer Research UK....

Comparative Study of Dysphagia-optimized Intensity Modulated Radiotherapy (Do-IMRT) and Standard Intensity Modulated Radiotherapy (S-IMRT) and Its Clinical Correlation in Head and Neck Cancer Patients.

Dosimetric sparing of critical swallowing structures like constrictor muscles and larynx can lead to improved functional outcomes in head and neck cancer patients treated by chemoradiation.... A total of 50 Patients with newly diagnosed, biopsy proven AJCC stage II-IV head and neck squamous cell cancers (HNSCC) were prospectively studied. 25 patients were randomized in each arm of Dysphagia... Patients in both arms showed significant (P <0.01 or P < 0.001) improvement in MDADI (global and composite), UW-QOL and Water Swallow Test scores. However, the improvements were found significantly hi... The Do-IMRT improves swallowing functions compared to S-IMRT in HNSCC patients treated with radical chemoradiation....

Intensity-modulated radiotherapy for cushing's disease: single-center experience in 70 patients.

Intensity-modulated radiotherapy (IMRT) is a modern precision radiotherapy technique for the treatment of the pituitary adenoma.... Aim to investigate the efficacy and toxicity of IMRT in treating Cushing's Disease (CD).... 70 of 115 patients with CD treated with IMRT at our institute from April 2012 to August 2021 were included in the study. The radiation doses were usually 45-50 Gy in 25 fractions. After IMRT, endocrin... At a median follow-up time of 36.8 months, the endocrine remission rate at 1, 2, 3 and 5 years were 28.5%, 50.2%, 62.5% and 74.0%, respectively. The median time to remission was 24 months (95%CI: 14.0... IMRT was a highly effective second-line therapy with low side effect profile for CD patients. Endocrine remission, tumor control and recurrence rates were comparable to previous reports on FRT and SRS...

Evaluation of the effect of intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc radiotherapy (VMAT) techniques on survival response in cell lines with a new radiobiological modeling.

The optimal radiobiological model, which assesses the biological effects of novel radiotherapy techniques that concurrently modify multiple physical factors, has not yet been defined. This study aimed... Clonogenic analysis, DNA double-strand break analysis, apoptosis, and cell cycle analysis were performed on cancer stem cell models, cancer models, and normal tissue cell models to assess radiation se... The segmented radiation approach used in IMRT applications enhanced radiosensitivity and cytotoxicity in the cancer models, while changes in dose rate had varying effects on cytotoxicity depending on ... The biological processes were influenced differently by dose rate, IMRT, and VMAT depending on the tumor cell type. The selection of the most appropriate technique is crucial in representing new radio...

Clinical significance of intensity-modulated radiotherapy (IMRT) to the distant metastatic lymph nodes for metastatic cervical cancer.

To retrospectively explore the clinical significance of radiotherapy to the distant metastatic lymph nodes (cervical/ clavicular/ mediastinal et al.) in metastatic cervical cancer. Hereinto, these cer... Metastatic cervical cancer only with the distant cervicothoracic metastatic lymph nodes (cervical/ clavicular/ mediastinal et al.), without distant parenchymal organs metastasis such as lung, liver, b... Overall, the median PFS was 9 months, and the median OS was 27 months. The subgroup analysis showed that for IB1-IVA, the median PFS was 11 months, and the median OS was 30.5 months. For IVB, the medi... Radiotherapy is beneficial to the distant metastatic lymph nodes (cervical/ clavicular/ mediastinal et al.), and could effectively bring the longer PFS and OS for metastatic cervical cancer....

Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis.

This study aimed to evaluate the survival and prognosis of older patients with nasopharyngeal carcinoma (NPC) who received intensity-modulated radiotherapy (IMRT) alone versus IMRT plus chemotherapy u... We enrolled 841 older patients with NPC aged 60 years and above without metastasis receiving IMRT alone or chemoradiotherapy from 2012 to 2019. The comorbidity was assessed by adult comorbidity evalua... A total of 841 patients with NPC were included in the study, there were 94 patients in the IMRT alone group and 747 patients in the chemoradiotherapy (CRT) group. After a 1:3 ratio PSM, 89 patients un... Combined modality therapy was associated with improved five-year OS and CSS in older adults with stage III-IV NPC, but was not associated with improved survival over IMRT alone in patients with stage ...

The application of 3D-printed oral stents in intensity-modulated radiotherapy for oropharyngeal cancer and their dosimetric effect on organs at risk.

This study investigates the accuracy of 3D-printed dental stents in intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer (OPC) and their dosimetric effects on normal tissues.... We selected 60 patients with OPC who underwent IMRT in the Department of Oncology, Special Medical Center of Army Medical University. These patients were randomly assigned into 3D-printed oral stent, ... No significant difference was observed in the conformity and uniformity of the target dose and the dose received by the spinal cord, larynx, and bilateral parotid glands among the three groups (P > 0.... For OPC patients undergoing IMRT, the application of 3D-printed oral stents can significantly reduce the exposure dose of the upper cheek and hard palate and decrease the occurrence of adverse events ...

Clinical treatment considerations in the intensity-modulated radiotherapy era for parotid lymph node metastasis in patients with nasopharyngeal carcinoma.

No specific irradiation guidelines have been proposed for parotid lymph node (PLN) metastasis in patients with nasopharyngeal carcinoma (NPC). This study aimed to explore the dose prescription and tar... With the NPC database from a big-data platform, 10,685 patients with primarily diagnosed, non-distant metastatic, histologically proven NPC and treated with intensity modulated radiotherapy (IMRT) at ... PLN metastases were identified in 275/10685 (2.5%) patients. Of 367 positive PLN, 199 were in superficial intra-parotid, followed by 70 in deep intra-parotid, 54 in subparotid and 44 in subcutaneous p... Based on the distribution pattern of PLN metastasis in NPC and the result of dose-finding study, involving the ipsilateral level VIII into low-risk clinical target volume (CTV2) is recommended for NPC...